SCHEMBL7400095

SCHEMBL7400095

CC(C)C[C@H](Nc1nc(-c2ccccc2)ns1)C(=O)N1CCC[C@H]1C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ACE P12821 9/20 0.51
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CNR2 P34972 1/20 0.47
TP53 P04637 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ADORA3 P0DMS8 1/20 0.45
MME P08473 1/20 0.45
MMEL1 Q495T6 1/20 0.45
NPC1 O15118 1/20 0.45
LMNA P02545 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ACE2 Q9BYF1 4/20 0.44
LTA4H P09960 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7644398 0.92 CNR2 (0.45) ACEMEN1KMT2ACNR2TP53
SCHEMBL28746793 0.92 CNR2 (0.45) ACEMEN1KMT2ACNR2TP53
SCHEMBL7402401 0.85 ACE (0.44) ACEMEN1KMT2AALOX15HSD17B10
SCHEMBL7404249 0.83 ACE (0.42) ACEMEN1KMT2AALOX15HSD17B10
SCHEMBL7447829 0.80 ACE (0.46) ACEMEN1KMT2AALOX15HSD17B10
SCHEMBL7404355 0.79 ALDH1A1 (0.47) ACEMEN1KMT2AHSD17B10LMNA
SCHEMBL7404341 0.79 ALDH1A1 (0.47) ACEMEN1KMT2AHSD17B10LMNA
Tromethamine SCHEMBL8195481 0.78 ACE (0.38) ACEMEN1KMT2AALOX15HSD17B10
SCHEMBL15251975 0.77 ACE (0.70) ACEMEN1KMT2AACE2
SCHEMBL15251977 0.77 ACE (0.70) ACEMEN1KMT2AACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6468977-B1 COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS APOTEX INC. (CA) 2002-10-22 US claimed
WO-2001090095-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 2001-11-29 WO claimed
US-6162791-A Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes APOTEX INC. (CA) 2000-12-19 US claimed
EP-1058690-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 2000-12-13 EP claimed
WO-1999045027-A1 THIADIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF CYSTEINE ACTIVITY DEPENDENT ENZYMES APOTEX INC. (CA) 1999-09-10 WO claimed
US-6468977-B1 COMPOUNDS USEFUL IN TREATMENT TREATMENT OF DISORDER AND/OR DISEASE CAUSED BY ACTIVITY OF ENZYMES SUCH AS HUMAN RHINOVIRUS 3C PROTEASE, TRANSGLUTAMINASE AND CATHEPSINS APOTEX INC. (CA) 2002-10-22 US disclosed
US-6162791-A Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes APOTEX INC. (CA) 2000-12-19 US disclosed